Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oral rehydration salts (ORS) produced by PUMC Pharmaceutical is an approved electrolyte and glucose formulation designed for the treatment and prevention of dehydration caused by acute diarrhea and gastroenteritis. The therapy leverages the sodium-glucose cotransport mechanism in the small intestine; the presence of glucose facilitates the active transport of sodium ions across the intestinal epithelium via the SGLT1 transporter, which in turn creates an osmotic gradient that promotes the passive absorption of water. This formulation is essential in managing fluid loss and electrolyte imbalances, particularly in pediatric and geriatric populations, and is a cornerstone of gastroenterology management for diarrheal diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oral rehydration salts.